Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. 1990

J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
Department of Hematology, Medizinische Hochschule MHH, University Medical Center, Hannover, FRG.

Recombinant interleukin-2 (rIL-2; EuroCetus, Amsterdam, Netherlands) was studied in an outpatient phase II trial in 14 patients with progressive metastatic renal carcinoma, malignant melanoma, and colorectal cancer. Escalating doses of rIL-2 were administered as subcutaneous bolus every 12 hours, starting at 0.3 million U/m2/d. A 100% dose increase occurred at weekly intervals, up to a maximum of 2.4 million U/m2/d. Responding patients or patients with stable disease after 4 weeks of rIL-2 (n = 9) were continued on maintenance therapy at 1.8 million U/m2 of rIL-2 administered once weekly. After 12 weeks of therapy, one renal cell cancer patient had a partial regression in lung metastases. Bolus injection of rIL-2 (1.2 million U/m2) resulted in peak serum levels of 25 to 30 U/ml. Toxicity of this regimen was moderate, with local inflammation at the injection sites, grade I-II (World Health Organization) malaise, nausea and/or vomiting, and fevers in 70% to 100% of patients treated. Thyroid dysfunction was observed in 10 patients receiving subcutaneous rIL-2; four of these patients had laboratory evidence of hyperthyroidism, and one had hypothyroidism. rIL-2-induced toxicity reversed spontaneously after cessation of treatment. In all patients receiving rIL-2, a dose-dependent increase in peripheral blood lymphocyte and eosinophil counts was noted, with a mean of 2.6 and 3.8 x 1,000/microliters after 4 weeks of therapy; mean lymphocyte and eosinophil counts were measured at 2.0 and 2.4 x 1,000/microliters in patients who received prior high-dose chemotherapy, compared with 3.2 and 5.1 x 1,000/microliters in those who did not.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007037 Hypothyroidism A syndrome that results from abnormally low secretion of THYROID HORMONES from the THYROID GLAND, leading to a decrease in BASAL METABOLIC RATE. In its most severe form, there is accumulation of MUCOPOLYSACCHARIDES in the SKIN and EDEMA, known as MYXEDEMA. It may be primary or secondary due to other pituitary disease, or hypothalamic dysfunction. Central Hypothyroidism,Primary Hypothyroidism,Secondary Hypothyroidism,TSH Deficiency,Thyroid-Stimulating Hormone Deficiency,Central Hypothyroidisms,Deficiency, TSH,Deficiency, Thyroid-Stimulating Hormone,Hormone Deficiency, Thyroid-Stimulating,Hypothyroidism, Central,Hypothyroidism, Primary,Hypothyroidism, Secondary,Hypothyroidisms,Primary Hypothyroidisms,Secondary Hypothyroidisms,TSH Deficiencies,Thyroid Stimulating Hormone Deficiency,Thyroid-Stimulating Hormone Deficiencies
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007964 Leukocytosis A transient increase in the number of leukocytes in a body fluid. Pleocytosis,Leukocytoses,Pleocytoses
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
October 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
August 1997, Cancer immunology, immunotherapy : CII,
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
June 1989, Cancer treatment reviews,
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
January 1991, Leukemia research,
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
January 1993, European journal of cancer (Oxford, England : 1990),
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
February 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
January 1997, Journal of immunotherapy (Hagerstown, Md. : 1997),
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
January 2001, Anticancer research,
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
January 1995, Cancer biotherapy,
J Atzpodien, and A Körfer, and P Evers, and C R Franks, and J Knüver-Hopf, and E Lopez-Hänninen, and M Fischer, and H Mohr, and I Dallmann, and M Hadam
July 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!